Alliance Global Partners analyst Scott Henry initiated coverage of Assertio Holdings with a Buy rating and $2.75 price target. The specialty pharma company recently launched the acquired asset Rolvedon and the firm believes that the market is not appreciating the ability of Assertio to drive consistent positive cashflow and acquire new products, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASRT:
- Assertio to Participate in Benchmark Healthcare Conference on May 21-22
- Assertio Holdings holder Buxton Helmsley releases letter from fraud examiner
- Assertio to Participate in AGP Healthcare Conference on May 21
- Assertio to Present at the Citizens JMP Life Sciences Conference in New York City
- ASRT Earnings this Week: How Will it Perform?
Questions or Comments about the article? Write to editor@tipranks.com